{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:00:22Z","timestamp":1773176422057,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Cancer Institute","award":["R01-CA097271"],"award-info":[{"award-number":["R01-CA097271"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10552-021-01551-w","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T06:04:25Z","timestamp":1642745065000},"page":"593-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between antidepressant use and second breast cancer event after ductal carcinoma in situ diagnosis: a nested case\u2013control study"],"prefix":"10.1007","volume":"33","author":[{"given":"Elizabeth T.","family":"Mansi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen E.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Tzu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole C.","family":"Loro\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1543-0743","authenticated-orcid":false,"given":"Christopher I.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"1551_CR1","unstructured":"American Cancer Society (2019) Breast Cancer Facts & Figures 2019\u20132020. American Cancer Society, Inc. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/breast-cancer-facts-and-figures-2019-2020.pdf. Accessed May 2, 2021"},{"issue":"8","key":"1551_CR2","first-page":"689","volume":"7","author":"LA Habel","year":"1998","unstructured":"Habel LA, Daling JR, Newcomb PA et al (1998) Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomark Prev 7(8):689\u2013696","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"1551_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1158\/1055-9965.EPI-13-0899","volume":"23","author":"VH McLaughlin","year":"2014","unstructured":"McLaughlin VH, Trentham-Dietz A, Hampton JM, Newcomb PA, Sprague BL (2014) Lifestyle factors and the risk of a second breast cancer after ductal carcinoma in situ. Cancer Epidemiol Biomark Prev 23(3):450\u2013460. https:\/\/doi.org\/10.1158\/1055-9965.EPI-13-0899","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"2","key":"1551_CR4","doi-asserted-by":"publisher","first-page":"pky020","DOI":"10.1093\/jncics\/pky020","volume":"2","author":"MR Flanagan","year":"2018","unstructured":"Flanagan MR, Tang M-TC, Baglia ML, Porter PL, Malone KE, Li CI (2018) Relationship between anthropometric factors and risk of second breast cancer among women with a history of ductal carcinoma in situ. JNCI Cancer Spectr 2(2):pky020. https:\/\/doi.org\/10.1093\/jncics\/pky020","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"1551_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/1055-9965.EPI-15-1063","volume":"25","author":"SB Brown","year":"2016","unstructured":"Brown SB, Hankinson SE, Arcaro KF, Qian J, Reeves KW (2016) Depression, antidepressant use, and postmenopausal breast cancer risk. Cancer Epidemiol Biomark Prev 25(1):158\u2013164. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-1063","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"1551_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1158\/1055-9965.EPI-17-0707","volume":"27","author":"KW Reeves","year":"2018","unstructured":"Reeves KW, Okereke OI, Qian J, Tamimi RM, Eliassen AH, Hankinson SE (2018) Depression, antidepressant use, and breast cancer risk in pre- and postmenopausal women: a prospective cohort study. Cancer Epidemiol Biomark Prev 27(3):306\u2013314. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0707","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"2_suppl","key":"1551_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/0269881107082624","volume":"22","author":"PW Harvey","year":"2008","unstructured":"Harvey PW, Everett DJ, Springall CJ (2008) Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol 22(2_suppl):20\u201327. https:\/\/doi.org\/10.1177\/0269881107082624","journal-title":"J Psychopharmacol"},{"key":"1551_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c693","volume":"340","author":"CM Kelly","year":"2010","unstructured":"Kelly CM, Juurlink DN, Gomes T et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693. https:\/\/doi.org\/10.1136\/bmj.c693","journal-title":"BMJ"},{"issue":"1","key":"1551_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13058-017-0928-0","volume":"20","author":"J Busby","year":"2018","unstructured":"Busby J, Mills K, Zhang S-D, Liberante FG, Cardwell CR (2018) Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study. Breast Cancer Res 20(1):4. https:\/\/doi.org\/10.1186\/s13058-017-0928-0","journal-title":"Breast Cancer Res"},{"issue":"6","key":"1551_CR10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/ije\/dyg155","volume":"32","author":"A Steingart","year":"2003","unstructured":"Steingart A, Cotterchio M, Kreiger N, Sloan M (2003) Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 32(6):961\u2013966. https:\/\/doi.org\/10.1093\/ije\/dyg155","journal-title":"Int J Epidemiol"},{"issue":"3","key":"1551_CR11","first-page":"307","volume":"14","author":"PG Moorman","year":"2003","unstructured":"Moorman PG, Grubber JM, Millikan RC, Newman B (2003) Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 14(3):307\u2013314","journal-title":"Epidemiology"},{"issue":"7","key":"1551_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/sj.bjc.6603017","volume":"94","author":"D Fulton-Kehoe","year":"2006","unstructured":"Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson MT, Weiss NS (2006) Use of antidepressant medications in relation to the incidence of breast cancer. Br J Cancer 94(7):1071\u20131078. https:\/\/doi.org\/10.1038\/sj.bjc.6603017","journal-title":"Br J Cancer"},{"issue":"4","key":"1551_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/pds.1719","volume":"18","author":"KJ Wernli","year":"2009","unstructured":"Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA (2009) Antidepressant medication use and breast cancer risk. Pharmacoepidemiol Drug Saf 18(4):284\u2013290. https:\/\/doi.org\/10.1002\/pds.1719","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1551_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10549-007-9828-9","volume":"112","author":"J Chubak","year":"2008","unstructured":"Chubak J, Buist DSM, Boudreau DM, Rossing MA, Lumley T, Weiss NS (2008) Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat 112(1):123\u2013132. https:\/\/doi.org\/10.1007\/s10549-007-9828-9","journal-title":"Breast Cancer Res Treat"},{"key":"1551_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv337","author":"R Haque","year":"2015","unstructured":"Haque R, Shi J, Schottinger JE et al (2015) Tamoxifen and antidepressant drug interaction among a cohort of 16 887 breast cancer survivors. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djv337","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1551_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10552-015-0689-y","volume":"27","author":"J Chubak","year":"2016","unstructured":"Chubak J, Bowles EJA, Yu O, Buist DSM, Fujii M, Boudreau DM (2016) Breast cancer recurrence in relation to antidepressant use. Cancer Causes Control 27(1):125\u2013136. https:\/\/doi.org\/10.1007\/s10552-015-0689-y","journal-title":"Cancer Causes Control"},{"issue":"2","key":"1551_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-016-3928-3","volume":"159","author":"A Valachis","year":"2016","unstructured":"Valachis A, Garmo H, Weinman J et al (2016) Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study. Breast Cancer Res Treat 159(2):293\u2013303. https:\/\/doi.org\/10.1007\/s10549-016-3928-3","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"1551_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2217\/fon-2020-0822","volume":"17","author":"R Li","year":"2021","unstructured":"Li R, Li X, Yan P et al (2021) Relationship between antidepressive agents and incidence risk of breast cancer: systematic review and meta-analysis. Future Oncol 17(9):1105\u20131124. https:\/\/doi.org\/10.2217\/fon-2020-0822","journal-title":"Future Oncol"},{"issue":"3","key":"1551_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1158\/1055-9965.EPI-17-0837","volume":"27","author":"ML Baglia","year":"2018","unstructured":"Baglia ML, Tang M-TC, Malone KE, Porter P, Li CI (2018) Family history and risk of second primary breast cancer after in situ breast carcinoma. Cancer Epidemiol Biomark Prev 27(3):315\u2013320. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0837","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"1551_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10552-018-1119-8","volume":"30","author":"ML Baglia","year":"2019","unstructured":"Baglia ML, Tang M-TC, Malone KE, Porter P, Li CI (2019) Reproductive and menopausal factors and risk of second primary breast cancer after in situ breast carcinoma. Cancer Causes Control 30(1):113\u2013120. https:\/\/doi.org\/10.1007\/s10552-018-1119-8","journal-title":"Cancer Causes Control"},{"issue":"10","key":"1551_CR21","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1158\/0008-5472.CAN-20-4100","volume":"81","author":"CI Li","year":"2021","unstructured":"Li CI, Flanagan MR, Tang M-TC, Porter PL, Malone KE (2021) Bisphosphonate use and breast cancer risk among women with ductal carcinoma in situ. Cancer Res 81(10):2799\u20132802. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-4100","journal-title":"Cancer Res"},{"issue":"19","key":"1551_CR22","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1200\/JCO.18.01779","volume":"37","author":"A DeCensi","year":"2019","unstructured":"DeCensi A, Puntoni M, Guerrieri-Gonzaga A et al (2019) Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol 37(19):1629\u20131637. https:\/\/doi.org\/10.1200\/JCO.18.01779","journal-title":"J Clin Oncol"},{"issue":"9793","key":"1551_CR23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771\u2013784. https:\/\/doi.org\/10.1016\/S0140-6736(11)60993-8","journal-title":"Lancet"},{"issue":"2","key":"1551_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10549-005-9056-0","volume":"95","author":"C Chien","year":"2006","unstructured":"Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR (2006) Antidepressant use and breast cancer risk. Breast Cancer Res Treat 95(2):131\u2013140. https:\/\/doi.org\/10.1007\/s10549-005-9056-0","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1551_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1586\/ecp.11.18","volume":"4","author":"DP Cronin-Fenton","year":"2011","unstructured":"Cronin-Fenton DP, Lash TL (2011) Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol 4(3):363\u2013377. https:\/\/doi.org\/10.1586\/ecp.11.18","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1551_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5014","volume":"354","author":"MM Donneyong","year":"2016","unstructured":"Donneyong MM, Bykov K, Bosco-Levy P, Dong Y-H, Levin R, Gagne JJ (2016) Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ 354:i5014. https:\/\/doi.org\/10.1136\/bmj.i5014","journal-title":"BMJ"},{"issue":"3","key":"1551_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3109\/02841860903575273","volume":"49","author":"TL Lash","year":"2010","unstructured":"Lash TL, Cronin-Fenton D, Ahern TP et al (2010) Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 49(3):305\u2013312. https:\/\/doi.org\/10.3109\/02841860903575273","journal-title":"Acta Oncol"},{"issue":"1","key":"1551_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10549-012-2330-z","volume":"137","author":"SB Dusetzina","year":"2013","unstructured":"Dusetzina SB, Alexander GC, Freedman RA, Huskamp HA, Keating NL (2013) Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004\u20132010. Breast Cancer Res Treat 137(1):285\u2013296. https:\/\/doi.org\/10.1007\/s10549-012-2330-z","journal-title":"Breast Cancer Res Treat"},{"key":"1551_CR29","unstructured":"Soltamox (tamoxifen citrate) Drug Label (2018). FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021807s005lbl.pdf. Accessed May 2, 2021"},{"key":"1551_CR30","doi-asserted-by":"publisher","DOI":"10.4081\/mi.2019.8115","author":"JJ Wedret","year":"2019","unstructured":"Wedret JJ, Tu TG, Paul D, Rousseau C, Bonta A, Bota RG (2019) Interactions between antidepressants, sleep aids and selected breast cancer therapy. Ment Illn. https:\/\/doi.org\/10.4081\/mi.2019.8115","journal-title":"Ment Illn"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-021-01551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-021-01551-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-021-01551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T04:28:14Z","timestamp":1646800094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-021-01551-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1551"],"URL":"https:\/\/doi.org\/10.1007\/s10552-021-01551-w","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}